文献速递消化系统肿瘤

HCV感染合并或未合并活动性HCC患者DAA治疗清除病毒对生存的影响:全国性队列研究

Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study.
PubMed 文献 · Eur J Cancer · 2025-11-14

该回顾性全国队列研究利用台湾TACR注册数据,纳入2205例接受DAA治疗的HCV感染成人HCC患者,其中1771例无活动性HCC、434例有活动性HCC。SVR与OS改善独立相关(aHR 0.45,95%CI 0.31-0.66,p<0.001)。在BCLC 0/A期活动性HCC患者中SVR组3年OS显著更高,在BCLC B/C期无活动性HCC患者中SVR组3年OS显著更高。结论提示BCLC 0/A期应早期启动DAA,BCLC B/C期DAA在肿瘤控制后获益最大。

要点

  • SVR与HCV感染HCC患者OS改善独立相关(aHR 0.45)。
  • BCLC 0/A期活动性HCC患者获得SVR后3年OS显著提高。
  • BCLC B/C期无活动性HCC患者获得SVR后3年OS显著提高。

核心结论

  • 对于BCLC 0/A期HCC,推荐早期启动DAA,即使存在活动性HCC。
  • 对于BCLC B/C期,DAA治疗在肿瘤控制后似乎获益最大。

研究设计与样本

  • 回顾性全国队列研究,利用台湾肝脏研究学会(TASL)HCV注册库(TACR)数据。
  • 共纳入2205例患者:1771例(80.3%)无活动性HCC,434例(19.7%)有活动性HCC。
  • 主要结局为总生存期(OS),计算SVR的调整比值比(aOR)和OS的调整风险比(aHR)。

主要发现

  • SVR与OS改善独立相关(aHR 0.45,95%CI 0.31-0.66;p<0.001)。
  • 在BCLC 0/A期活动性HCC患者中,SVR组3年OS率显著更高(71.7%,95%CI 64.6-77.7% vs. 39.9%,95%CI 15.6-63.5%;p=0.007)。
  • 在BCLC 0/A期无活动性HCC患者中,SVR组3年OS率非显著更高(84.2%,95%CI 81.7-86.4% vs. 70.0%,95%CI 44.2-85.6%;p=0.181)。
  • 在BCLC B/C期无活动性HCC患者中,SVR组3年OS率显著更高(76.2%,95%CI 70.2-81.2% vs. 24.7%,95%CI 5.3-51.3%;p<0.001)。
  • 在BCLC B/C期活动性HCC患者中,SVR组3年OS率无显著差异(58.6%,95%CI 47.9-67.7% vs. 57.1%,95%CI 17.2-83.7%;p=0.922)。

关键数值与推荐

  • SVR与OS改善独立相关:aHR 0.45(95%CI 0.31-0.66;p<0.001)。
  • BCLC 0/A期活动性HCC:SVR组3年OS率71.7%(95%CI 64.6-77.7%)vs. 非SVR组39.9%(95%CI 15.6-63.5%),p=0.007。
  • BCLC B/C期无活动性HCC:SVR组3年OS率76.2%(95%CI 70.2-81.2%)vs. 非SVR组24.7%(95%CI 5.3-51.3%),p<0.001。

临床怎么用

  • 对BCLC 0/A期合并活动性HCC的HCV感染者,应考虑早期启动DAA治疗。
  • 对BCLC B/C期患者,DAA治疗宜在肿瘤控制后实施以最大化生存获益。

局限性

  • 回顾性队列设计可能存在选择偏倚和未测量混杂因素。
  • 部分亚组样本量较小,置信区间较宽,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The survival benefit of direct-acting antiviral (DAA) in hepatitis C virus (HCV)-infected patients with or without active hepatocellular carcinoma (HCC) remains debated. This study aimed to clarify this issue. METHODS: This retrospective nationwide cohort study utilized data from the Taiwan Association for the Study of the Liver (TASL) HCV Registry (TACR) to identify adults with HCC who received DAA therapy for HCV between December 2013 and December 2020. Patients with other viral infections, prior liver transplantation, non-HCC malignancies, or terminal-stage HCC were excluded. The primary outcome was overall survival (OS). The adjusted odds ratio (aOR) for sustained virological response (SVR) and the adjusted hazard ratio (aHR) for OS were calculated. FINDINGS: A total of 2205 patients were included: 1771 (80.3 %) without active HCC and 434 (19.7 %) with active HCC. SVR was independently associated with improved OS (aHR 0.45, 95 % CI: 0.31-0.66; p < 0.001). In Barcelona Clinic Liver Cancer (BCLC) stage 0/A, the 3-year OS rate was significantly higher in the SVR group amongst patients with active HCC (71.7 %, 95 % CI 64.6-77.7 % vs. 39.9 %, 95 % CI 15.6-63.5 %; p = 0.007) but non-significantly higher amongst those without active HCC (84.2 %, 95 % CI 81.7-86.4 % vs. 70.0 %, 95 % CI 44.2-85.6 %; p = 0.181). In BCLC stage B/C, the 3-year OS rate was significantly higher in the SVR group amongst patients without active HCC (76.2 %, 95 % CI 70.2-81.2 % vs. 24.7 %, 95 % CI 5.3-51.3 %; p < 0.001) but not amongst those with active HCC (58.6 %, 95 % CI 47.9-67.7 % vs. 57.1 %, 95 % CI 17.2-83.7 %; p = 0.922). CONCLUSION: For BCLC stage 0/A HCC, early DAA initiation is recommended, even with active HCC. In BCLC stage B/C, DAA therapy appears most beneficial after tumor control.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lee TY, Yang SS, Tsai PC, et al. Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study. Eur J Cancer. 2025. PMID: 41274170. doi:10.1016/j.ejca.2025.116109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。